Pharmaceutical

Biogen’s higher dose Spinraza under review by US and EU regulators

Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.

Jan 24, 2025 - 06:00
Biogen’s higher dose Spinraza under review by US and EU regulators
Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.
Read the original article

Tags:

Previous Article

Magazine: The biggest challenges clinical trials will face in 2025

Next Article

Bladder cancer: Shaping the future of global clinical trials

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: A Harvard course seeks to put food on the table in medical education

STAT+: A Harvard course seeks to put food on the table ...

Jan 22, 2024

STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest

STAT+: Here are the cancer drugs Pfizer thinks could re...

Feb 29, 2024

The science of viscous drug product filling: Pumps, pressure, and process optimization

The science of viscous drug product filling: Pumps, pre...

Oct 16, 2024